Protein biomarker immunoassays opportunities and challenges

Drug Discovery World

Volumn 12, Issue 1, 2010, Pages 19-28

  Qoronfleh, M Walid ^a,b   Lindpaintner, Klaus ^c,d  

^a SDIX   (United States)

^b NextGen Sciences ^*  (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Molecular Medicines Policy and External Affairs   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN;

DNA DETERMINATION; DRUG INDUSTRY; DRUG RESEARCH; IMMUNOASSAY; PROTEIN DETERMINATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATIONAL RESEARCH; VALIDATION PROCESS;

EID: 79952230979     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95.
2. Gerber, Rush, Stemman, Kirscher, Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. PNAS 100: 6940-6945.
3. Anderson, NL, Anderson, NG, Haines. LR, Hardie, DB, Olafson, RW, Pearson, TW (2004). Mass spectrometric quantification of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Anti-bodies (SISCAPA). J. Proteome Research 3: 235-244.
4. Cummings, J, Ward, TH, Greystoke, A, Ranson, M and Dive, C (2008). Biomarker method validation in anticancer drug development British J Pharmacology 153: 646-656.
5. Usdin, S (2008). Getting real about biomarkers. SciBx 1 (13): 1-4.